Podcasts about biotech

Live from Proof of Talk Paris 2025, this special episode of The Edge of Show dives deep into the explosive convergence of AI, blockchain, and decentralized infrastructure.We sat down with three visionary companies shaping the future of artificial intelligence and machine economies. First we spoke with Humayun Sheikh, the CEO of Fetch.ai, he breaks down the launch of ASI One and explains how agent-based AI is reshaping everything from enterprise tools to decentralized infrastructure. Next we welcomed back Janet Adams, the COO of SingularityNet and Co-Founder of the Artificial Superintelligence Alliance. she offers a bold vision for decentralized AGI, diversity in AI development, and why she believes decentralized models will outperform big tech in the coming AI arms race. And lastly the co-founders of Peaq, Leonard Dorlöchter & Till Wendler, join us to discuss how machines are starting to own and operate assets, collaborate across borders, and drive real-world revenue in smart cities around the world.This episode is packed with insight, strategy, and optimism about how AI and decentralization are shaping the next decade of global innovation.Support us through our Sponsors! ☕

A handful of encouraging signals is cause for cautious optimism for biotech headed into the second half of the year — companies have been able to parlay strong data into follow-on capital and M&A activity is picking up. That said, the IPO market continues to be closed and concerns about U.S. drug pricing and FDA stability continue to weigh on expectations for a robust near-term sector recovery.Special guest Megan Hooton from IQVIA Biotech joins BioCentury's analysts on a special edition of the podcast to discuss key indicators of progress for the biopharma sector. Hooton is president of IQVIA Biotech, which sponsored this episode of the pod.View full story: https://www.biocentury.com/article/656614#biotech #biopharma #pharma #lifescience #BiotechTrends #ClinicalTrials #GeneTherapy #CellTherapy00:01 – Sponsor Message: IQVIA Biotech02:37 – Biotech Markets06:41 – Clinical Highlights10:26 – Insights from Meg Hooton23:10 – Advanced TherapiesTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

What does it really take to land a successful biotech partnership—and what makes a deal fall apart? In this episode, host Elaine Hamm, PhD, sits down with Renee Williams, PhD, MBA, Founder and Managing Partner of Williams Biotech Consulting and Independent Board Director for AGS Therapeutics. With experience across major pharma companies like Eli Lilly and Janssen, Renee shares hard-earned insights from the front lines of dealmaking. From communication missteps to finding the right partner, she explains how to navigate biotech partnerships with clarity, confidence, and strategy. In this episode, you'll learn: Why overcommunication is key to every stage of the deal process. How to identify (and avoid) red flags in strategic partnerships. What scientists need to know to transition into biotech business roles. Whether you're negotiating a licensing deal or dreaming of your first exit, this episode is packed with advice you won't want to miss. Links: Connect with Renee Williams, PhD, MBA, and check out Williams Biotech Consulting and AGS Therapeutics. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about Eli Lilly and Janssen Pharmaceutical. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Novo Nordisk has announced Maziar Mike Doustdar as its new CEO, along with a 5% reduction in its 2025 sales guidance. This decision comes as a response to the slowed growth of its semaglutide franchise in the U.S. Senate Democrats are currently looking into HHS Secretary RFK Jr.'s controversial move to dismiss all 17 members of the CDC's vaccine advisory committee. Astrazeneca CEO Pascal Soriot emphasized the importance of global collaboration in pharmaceutical research and development. Merck has allocated $3 billion to support upcoming product launches. In a surprising turn of events, the FDA has reversed its decision on Sarepta, now permitting DMD gene therapy for ambulatory patients.

In today's episode I was joined by Ashley Argiras, VP of Quality at Recursion.I really wanted to speak to Ashley because she's helping redefine what quality leadership looks like in a tech-enabled, platform biotech - and she's doing it by shifting how people think, not just how they work.Ashley's journey into science started in high school - not in a lab, but making ice cream during chemistry class. That moment sparked a lifelong curiosity that took her to Indiana University, and eventually into clinical research. She began her career as a CRA at Eli Lilly, where she visited trial sites and became the first line of quality, working hands-on with investigators to ensure patient safety and protocol integrity.That experience gave her a real-world understanding of what quality means at the ground level, and it's shaped the way she leads today: rooted in purpose, driven by questions, and always looking for better ways to serve patients.We talk about the following:

Lexi Silver is 15 years old. She lost both of her parents before she turned 11. That should tell you enough—but it doesn't. Because Lexi isn't here for your pity. She's not a sob story. She's not a trauma statistic. She's a writer, an advocate, and one of the most emotionally intelligent people you'll ever hear speak into a microphone.In this episode, Lexi breaks down what grief actually feels like when you're a kid and the adults around you just don't get it. She talks about losing her mom on Christmas morning, her dad nine months later, how the system let her down, and how Instagram trolls tell her she's faking it for attention. She also explains why she writes, what Experience Camps gave her, how she channels anger into poems, and what to say—and not say—to someone grieving.Her life isn't a Netflix drama. But it should be.And by the way, she's not “so strong.” She's just human. You'll never forget this conversation.RELATED LINKS• Lexi on Instagram: @meet.my.grief• Buy her book: The Girl Behind Grief's Shadow• Experience CampsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week's deal between GSK and Jiangsu Hengrui is a prime example of how Western biopharmas have begun to recognize the innovation and opportunities being fostered in China — and how it's no longer all about fast followers.On the latest BioCentury This Week podcast, BioCentury's analysts put the collaboration between GSK and Jiangsu Hengrui Pharmaceuticals, two of the most active cross-border dealmakers, into the context of East-West dealmaking over the past 30 months, assessing the innovation that is driving the rush to partner with biotechs in China, Japan, South Korea and beyond, and the types of companies looking to Asia for assets.BioCentury's analysts also discuss Steve Bates' outsized role in building the U.K. biotech hub, as he readies to take on a new role in the U.K. government. They examine new VC funds from Omega Funds and Brandon Capital, FDA's new national priority voucher pilot program, and fallout from how FDA and  Sarepta Therapeutics handled the deaths of four patients who had received the biotech's gene therapies. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/656592#biotech #biopharma #pharma #lifescience #EastWestDealmaking #ChinaBiotech #UKBiotech #FDAPolicy00:01 - Sponsor Message: IQVIA Biotech02:48 - Asia Deals Landscape17:32 - Steve Bates & U.K. Biotech25:46 - FDA's New Voucher Pilot31:01 - New VC Funds35:28 - SareptaTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. GSK has entered a partnership with Hengrui worth up to $12 billion, focusing on the COPD candidate HRS-9821. The FDA's new voucher policy has caused confusion among experts, as it lacks clear definition and was announced without public input. The American Medical Association urges RFK Jr. to maintain the preventive task force, and Sarepta denies a patient death is linked to Elevidys as the FDA launches a probe. Biopharma companies are leaning towards holistic treatments for Alzheimer's, while Atai-partnered schizophrenia drug fails in a mid-stage trial. Boehringer partners with Irish startup Re-Vana in a $1 billion+ eye deal.As the Alzheimer's space becomes more competitive, biopharma companies are focusing on holistic treatments beyond disease-modifying drugs like Leqembi and Kisunla. Companies such as Bristol Myers Squibb, Acadia, Otsuka, and Lundbeck are renewing their search for symptomatic treatments. Five upcoming data drops could potentially lead to more effective therapies for Alzheimer's. Sarepta Therapeutics is facing challenges due to safety concerns surrounding its gene therapies, leading to a drop in stock value. The FDA's new voucher program aims to offer accelerated pathways for drugs meeting certain criteria, but experts criticize the lack of transparency and public input in the policy's announcement. Sarepta's future is uncertain as the FDA considers a new study for Elevidys, and the EU issues a negative opinion on the drug. Other news includes delays in the FDA decision on GSK's Blenrep, AstraZeneca's PIII win with nanobody treatment for myasthenia gravis, and the removal of thimerosal from influenza vaccines. George Tidmarsh has been appointed as the new chief of FDA's CDER.

Mit KI erleben wir ”eine Revolution, die größer ist als die Erfindung des Internets”, sagt Handelsblatt-Chefredakteur Sebastian Matthes im Podcast-Interview mit Verena Gründel. “Wir fokussieren uns aber im Moment bei KI sehr auf die Anwendung, die wir im Alltag nutzen können”, bemerkt er. Dabei werde im Moment die nächste Welle der KI angestoßen: die Automatisierung von Geschäftsprozessen oder von Produktionsanlagen. Also im weiteren Sinne - die industrielle KI. “Und wo in aller Welt soll die beste industrielle KI entstehen, wenn nicht in Europa, wo die meisten und die erfolgreichsten Industriebetriebe sind?”Wie wir die Weichen dafür schaffen, dazu hat er klare Vorstellungen. Ein wichtiger Baustein sei es, aus Lehre, Forschung und Entwicklung vermehrt skalierfähige Geschäftsmodelle zu entwickeln. Seine drei Erfolgsstrategien:Wir müssen verstehen, in welchen Feldern wir als Land in den nächsten zehn Jahren eine Rolle spielen wollen. Für diese Industrien müssten die besten Rahmenbedingungen geschaffen werden.Wir müssen die momentan große Chance nutzen, Wissenschaftlerinnen und Wissenschaftler aus den USA anzuziehen, mit entsprechenden Programmen oder hochdotierten Professorenstellen.Wir müssen verstehen, dass die Zukunft Deutschlands nur Europa lauten kann und wir alles dafür tun müssen, dass dieser Binnenmarkt endlich vollendet wird.5 Fun Facts aus dem Gespräch:Ein “Blatt ohne Blätter: 85 Prozent der Handelsblatt-Abos sind bereits digital.In wenigen Jahren könnte schon ein Drittel des deutschen Risikokapitals in das erfolgreiche Münchener UnternehmerTUM-Cluster fließen, prognostiziert er und fragt sich, warum nicht alle anderen Exzellenz-Universitätsstandorte dieses System einfach kopieren.Um Geld für Start-ups macht er sich keine Sorgen: „Wir haben ein Mindset-Problem – kein Geldproblem.“ Denn in Deutschland liege viel Kapital brach. Es fehlt vor allem an Strukturen und dem unternehmerischen Selbstverständnis, um das Geld in das Wachstum der Wirtschaft zu investieren.Matthes sieht enorm viel Wachstumspotenzial für Deutschland in der Biotech- und Medizin-Branche. “In den nächsten zehn Jahren könnte sie die Autoindustrie an Relevanz, was Wertschöpfung angeht, übertrumpfen.”Matthes prognostiziert 1 bis 2 Prozent Wachstum für Deutschland in zwei Jahren – aber nur, wenn jetzt die passenden Reformen von der Politik umgesetzt werden.Hör jetzt rein und lass dich inspirieren.Und komm am 17. und 18. September 2025 zur DMEXCO nach Köln - sichere dir hier dein Ticket: https://dmexco.com/de/tickets/

We love to hear from our listeners. Send us a message. On this week's episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing  a radiopharmaceutical company focused on oncology. Dr. Delpassand discusses the current trends in radiopharmaceutical drug development, the differences between alpha- and beta-emitting isotopes, overcoming manufacturing and supply chain challenges and restraints, and building strategic partnerships with companies like Curium, Fusion (now part of AstraZeneca), and Sanofi. He also offers specific advice to physician-entrepreneurs interested in building their own drug development companies. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Metis Consulting Services ML Bradley welcomed Kara Harrison to the "Queens of Quality" podcast, where Kara Harrison shared her extensive career journey in quality assurance, from the USDA and FDA to various consulting roles. Both Kara Harrison and Metis Consulting Services ML Bradley discussed the evolution of the consulting industry, emphasizing the importance of clear client scope and the challenges posed by clients who insist on incorrect approaches. A key talking point centered on the misconception among sponsors that outsourcing absolves them of responsibility, particularly concerning vendor qualification and oversight, which directly contradicts regulatory guidelines such as ICH E6R3.

The line between groundbreaking innovation and controversial ownership blurs when scientists begin creating life in laboratories. What happens when your invention isn't just a device or chemical formula, but a living, breathing, self-replicating organism that refuses to stay contained within traditional legal boundaries?Synthetic biology—the field where engineering meets genetics—has created a perfect storm for intellectual property law. Scientists can now design cells like software, program bacteria to clean oil spills, and edit genes with CRISPR technology. But who owns these inventions when they start reproducing themselves?From the landmark 1980 Chakrabarty decision that first allowed patents on genetically modified bacteria to the controversial Myriad Genetics case that determined human genes cannot be patented, we explore the fascinating legal battles that shaped biotech innovation. We journey through courtrooms worldwide where judges grappled with unprecedented questions: Can you patent a cloned sheep? Should farmers be allowed to replant patented seeds? Does traditional knowledge about medicinal plants deserve protection from corporate "biopiracy"?The legal landscape continues evolving, with a brand new WIPO treaty requiring disclosure of genetic resources' origins in patent applications. This represents a major shift toward transparency and fairness, especially for communities whose biodiversity and traditional knowledge have contributed to modern innovations.Whether you're a scientist, lawyer, entrepreneur, or simply curious about the legal frameworks governing emerging technologies, this episode offers crucial insights into how intellectual property systems are adapting to the brave new world where the line between invention and life itself becomes increasingly blurred. Subscribe to Intangiblia for more explorations of the fascinating intersection of law, technology, and innovation.Send us a text

Science communication expert Lisa Warshaw and scientist Rob Signer, Ph.D., offer a practical guide to turning complex research into clear, memorable stories. They explain why strong openings, simple messages, vivid analogies, and visual storytelling are essential to making science resonate. The talk includes tips on avoiding jargon, using soundbites effectively, and preparing for high-stakes moments like media interviews and conference Q&As. Warshaw draws on her experience in global biotech and healthcare communications, while Signer shares real-world lessons from academic science and public engagement. Together, they highlight how clarity and creativity can elevate a researcher's voice, build trust with diverse audiences, and drive impact across fields. The session is filled with actionable insights for scientists aiming to connect their work with the world. Series: "Stem Cell Channel" [Humanities] [Science] [Show ID: 40460]

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The European Medicines Agency's CHMP did not recommend approving Elevidys for ambulatory patients with Duchenne muscular dystrophy, dealing a blow to Sarepta. FDA is rumored to request new data for Elevidys, leading to uncertainty as FDA considers a new study for the drug. In other news, Eli Lilly commits $856 million to Gate Bioscience for a new class of medicines, while Rocket trims headcount and pipeline focus. Roche also drops an early obesity asset as layoffs continue in the biopharma industry, with companies like Adicet optimizing their pipelines. Novartis makes a billion-dollar drug discovery deal with Matchpoint, and the FDA opens a pilot run of the commissioner voucher program.Stay tuned for more updates on the latest developments in the pharmaceutical and biotech world.

Science communication expert Lisa Warshaw and scientist Rob Signer, Ph.D., offer a practical guide to turning complex research into clear, memorable stories. They explain why strong openings, simple messages, vivid analogies, and visual storytelling are essential to making science resonate. The talk includes tips on avoiding jargon, using soundbites effectively, and preparing for high-stakes moments like media interviews and conference Q&As. Warshaw draws on her experience in global biotech and healthcare communications, while Signer shares real-world lessons from academic science and public engagement. Together, they highlight how clarity and creativity can elevate a researcher's voice, build trust with diverse audiences, and drive impact across fields. The session is filled with actionable insights for scientists aiming to connect their work with the world. Series: "Stem Cell Channel" [Humanities] [Science] [Show ID: 40460]

Science communication expert Lisa Warshaw and scientist Rob Signer, Ph.D., offer a practical guide to turning complex research into clear, memorable stories. They explain why strong openings, simple messages, vivid analogies, and visual storytelling are essential to making science resonate. The talk includes tips on avoiding jargon, using soundbites effectively, and preparing for high-stakes moments like media interviews and conference Q&As. Warshaw draws on her experience in global biotech and healthcare communications, while Signer shares real-world lessons from academic science and public engagement. Together, they highlight how clarity and creativity can elevate a researcher's voice, build trust with diverse audiences, and drive impact across fields. The session is filled with actionable insights for scientists aiming to connect their work with the world. Series: "Stem Cell Channel" [Humanities] [Science] [Show ID: 40460]

Science communication expert Lisa Warshaw and scientist Rob Signer, Ph.D., offer a practical guide to turning complex research into clear, memorable stories. They explain why strong openings, simple messages, vivid analogies, and visual storytelling are essential to making science resonate. The talk includes tips on avoiding jargon, using soundbites effectively, and preparing for high-stakes moments like media interviews and conference Q&As. Warshaw draws on her experience in global biotech and healthcare communications, while Signer shares real-world lessons from academic science and public engagement. Together, they highlight how clarity and creativity can elevate a researcher's voice, build trust with diverse audiences, and drive impact across fields. The session is filled with actionable insights for scientists aiming to connect their work with the world. Series: "Stem Cell Channel" [Humanities] [Science] [Show ID: 40460]

Science communication expert Lisa Warshaw and scientist Rob Signer, Ph.D., offer a practical guide to turning complex research into clear, memorable stories. They explain why strong openings, simple messages, vivid analogies, and visual storytelling are essential to making science resonate. The talk includes tips on avoiding jargon, using soundbites effectively, and preparing for high-stakes moments like media interviews and conference Q&As. Warshaw draws on her experience in global biotech and healthcare communications, while Signer shares real-world lessons from academic science and public engagement. Together, they highlight how clarity and creativity can elevate a researcher's voice, build trust with diverse audiences, and drive impact across fields. The session is filled with actionable insights for scientists aiming to connect their work with the world. Series: "Stem Cell Channel" [Humanities] [Science] [Show ID: 40460]

Kyle Touchstone, Director of Raleigh Economic Development, shares with us how Raleigh became the top-ranked large city in the US, according to the Milken Institute. Kyle and show host Gene Tunny discuss the city's success in biotech, AI, quantum computing, and advanced manufacturing—all underpinned by the world-class universities and innovation ecosystem of North Carolina's Research Triangle. The conversation also explores Raleigh's growing role in the gaming industry, including its connection to Epic Games—the creator of Fortnite—and the rise of eSports in the region.Please email Gene your thoughts on this episode via contact@economicsexplored.com.TimestampsRaleigh's Economic Growth and Milken Institute Ranking (0:00)Industry Sectors and Infrastructure in North Carolina (5:17)Significant Announcements and Investments (7:23)Population Growth and Quality of Life (12:23)Entrepreneurial Ecosystem and Community Support (15:08)Tax Policy and Economic Development (15:35)Quantum Computing and AI (19:49)Sports and Entertainment (43:40)eSports and Gaming (47:55)Lessons in Economic Development (50:39)TakeawaysTop Rankings: Raleigh was named the #1 best-performing large city by the Milken Institute and is part of the #1 state for business (North Carolina, per CNBC).Research Triangle Advantage: Home to NC State, Duke, and UNC Chapel Hill, the Research Triangle fuels innovation with top-tier talent and research.Massive Investment: Biotech firms, such as Biogen, Amgen, and Genentech, have invested billions, drawn by the infrastructure, affordability, and access to research.Quantum & AI Leadership: IBM's quantum hub and regional AI focus are positioning Raleigh as a leader in next-gen computing.Entrepreneurial Ecosystem: Startups like Pendo and social enterprises like 321 Coffee thrive thanks to a strong support network and educational institutions.Links relevant to the conversationRaleigh, NC and Gainesville, GA Top Milken Institute's 2025 Annual Ranking of Best-Performing Cities:https://milkeninstitute.org/content-hub/news-releases/raleigh-nc-and-gainesville-ga-top-milken-institutes-2025-annual-ranking-best-performing-citiesRaleigh Economic Development:https://www.raleighecondev.org/Zoom catch up with show host Gene TunnyJoin Gene and other listeners for a catch-up on Zoom on Thursday, 31 July at: 21.30 to 22.30 AEST/GMT+10 (Australian East Coast time)12.30 to 13.30 BST/GMT+1 (British Summer time)07.30 to 08.30 EDT/GMT-4 (US East Coast time)The link to the Zoom room is:https://us02web.zoom.us/j/9471595560RSVP by 20.00 GMT+10 on 31 July to contact@economicsexplored.comLumo Coffee promotion10% of Lumo Coffee's Seriously Healthy Organic Coffee.Website: https://www.lumocoffee.com/10EXPLOREDPromo code: 10EXPLORED 

As AI infiltrates every aspect of our lives, who are some of the people behind this huge inflection point? In this special three-part series, you'll hear from the people predicting and shaping our tech future. Host Manoush Zomorodi reports on the latest and revisits her favorite conversations with the minds crafting the digital world we live in today: what they've gotten right — and wrong — and where they think we're headed next. Part 3 features biochemist Jennifer Doudna, neurologist Tom Oxley and legal scholar Nita Farahany.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

In this episode of Crazy Wisdom, Stewart Alsop sits down with the masked collective known as the PoliePals—led by previous guest Cathal—to explore their audacious vision of blending humans, nature, and machines through cryptographic reality verification and decentralized systems. They talk about neural and cryptographic projector-camera technologies like the “truth beam” and “reality transform,” analog AI using optical computing, and how open protocols and decentralized consensus could shift power away from corporate control. Along the way, they share stories from Moad's chaotic tinkering workshop, Meta's precise Rust-coded Alchemy project, and Terminus Actual's drone Overwatch. For links to their projects, visit Poliebotics on Twitter and Poliebotics on GitHub.Check out this GPT we trained on the conversationTimestamps00:05 Neural and cryptographic projector-camera systems, reality transform for art and secure recordings, provably unclonable functions.00:10 Moad's GNOMAD identity, chaotic holistic problem-solving, tinkering with tools, truth beam's manifold mapping.00:15 Terminus Actual's drone Overwatch, security focus, six hats theory, Lorewalker's cryptic mathematical integrations.00:20 Analog AI and optical computing, stacked computational layers, local inference, physical reality interacting with AI.00:25 Meta's Alchemy software, music-driven robotics, precise Rust programming, contrast with neural network unpredictability.00:30 Decentralization, corporate dependency critique, hardware ownership, open protocols like Matrix, web of trust, Sybil attacks.00:35 Truth beam feedback loops, decentralized epistemology, neo-feudalism, Diamond Age references, nano drone warfare theory.00:40 Biotech risks, lab truth beams for verification, decentralized ID systems, qualitative consensus manifolds.00:45 Maker culture insights, 3D printing community, iterative prototyping, simulators, recycling prints.00:50 Investment casting, alternative energy for classic cars, chaotic hardware solutions, MoAD workshop's mystical array.00:55 Upcoming PolyPals content, Big Yellow Island recordings, playful sign-offs, decentralized futures.Key InsightsThe PoliePals are pioneering a system that combines cryptographic models, neural projector-camera technologies, and decentralized networks to create tools like the “truth beam” and “reality transform,” which verify physical reality as a provably unclonable function. This innovation aims to secure recordings and provide a foundation for trustworthy AI training data by looping projections of blockchain-derived noise into reality and back.Moad's character, the GNOMAD—a hybrid of gnome and nomad—embodies a philosophy of chaotic problem-solving using holistic, artful solutions. His obsession with edge cases and tinkering leads to surprising fixes, like using a tin of beans to repair a broken chair leg, and illustrates how resourcefulness intersects with decentralization in practical ways.Terminus Actual provides a counterbalance in the group dynamic, bringing drone surveillance expertise and a healthy skepticism about humanity's inherent decency. His perspective highlights the need for security consciousness and cautious optimism when developing open systems that could otherwise be exploited.Meta's Alchemy project demonstrates the contrast between procedural precision and chaotic neural approaches. Written entirely in Rust, it enables music-driven robotic control for real-world theater environments. Alchemy represents a future where tightly optimized code can interact seamlessly with hardware like Arduinos while remaining resistant to AI's unpredictable tendencies.The episode explores how decentralization could shape the coming decades, likening it to a neo-feudal age where people consciously opt into societies based on shared values. With open protocols like Matrix, decentralized IDs, and webs of trust, individuals could regain agency over their data and technological ecosystems while avoiding corporate lock-in.Optical computing experiments reveal the potential for analog AI, where stacked shallow computational layers in physical media allow AI to “experience” sensory input more like a human. Though still speculative, this approach could produce richer, lower-latency responses compared to purely digital models.Maker culture and hardware innovation anchor the conversation in tangible reality. Moad's MoAD workshop, filled with tools from industrial sewing machines to 3D printers and lathes, underscores how accessible technologies are enabling chaotic creativity and recycling systems. This grassroots hardware tinkering aligns with the PoliePals' broader vision of decentralized, cooperative technological futures.

In this episode of Grow Everything, hosts Karl and Erum dive into the world of community biology with Dr. Casey Lardner, Executive Director of Genspace. They explore how this groundbreaking Brooklyn lab is reimagining who gets to participate in science — and how. From radical accessibility and inclusive education to the launch of Gotham Foundry, Casey shares how Genspace is cultivating a culture of curiosity, creativity, and collaboration. This is a conversation about science as a shared resource, where artists, bioengineers, and everyday citizens all have a seat at the bench.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters:00:00:00 - Welcome to Grow Everything: Where Bio Meets the World00:00:25 - Guest Co-Host Sabriya Stukes Drops In — Backyard BBQ to Biotech00:01:18 - What's Buzzing in Biotech: Founders, VCs & Sound Baths00:03:48 - Redefining Community: Beyond Buzzwords in Bio00:06:38 - Genspace Unveiled: Brooklyn's Portal to Public Science00:10:41 - From Chemistry to Community: Casey's Unexpected Path to Genspace00:13:40 - Inside Genspace: Culture, Creativity, and the Curious00:22:06 - Radical Access: Building Biotech for Everyone00:28:55 - Live from Ilmar 2025: Big Ideas, Big Shifts00:37:35 - What's Next? Introducing Gotham Foundry00:39:25 - Fueling Founders: How Genspace Sparks Startups00:40:23 - Why NYC is the Place to Grow Bio Right Now00:41:53 - Stay Curious: The Secret Ingredient in Science00:43:26 - Can AI Help Democratize Biology? Genspace Thinks So00:46:51 - Where Art Meets Genome: The Power of Story in Science00:51:28 - Bold Visions: What the Future Looks Like at Genspace00:55:49 - The Pulse of NYC Biotech: Reflections and Real TalkLinks and Resources:Genspace OpenPlant Genspace - growing your own insulin?Asilomar ReportsGotham FoundryIndieBioNewLab BioLabsBioFab Fair: Use promo code: GROW10 Story ColliderCaveat Facts MachineTopics Covered: biotech, community biotech, community hub, biomaterials, bio-based ingredients, GenspaceHave a question or comment? Message us here:Text or Call (804) 505-5553 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email: groweverything@messaginglab.comMusic by: NihiloreProduction by: Amplafy Media

Jason Akus, Head of Healthcare Investing for Aberdeen Investments, says that current conditions for healthcare and biotech investing are making for "one of the most challenging, difficult and dislocated environments I've seen." While trades in technology, artificial intelligence and the Magnificent Seven stocks have driven the stock market back to record-high levels, Akus notes that healthcare has been flat in 2025 with biotech faring only slightly better; moreover, healthcare has been flat for two years, while the Standard & Poor's 500 was gaining about 40 percent. "It's not to say that healthcare is not growing earnings ... it's just been left behind" more attractive growth sectors. Akus says that creates a lot of opportunities and attractive valuations for healthcare and biotech investors, as he sees market conditions changing and "green shoots" emerging as long-term innovations and developments pay off.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has dropped an early-stage obesity asset, CT-173, citing lack of competitiveness. Novartis has entered into a drug discovery deal with Matchpoint Therapeutics, acquiring global rights on all molecules for several inflammatory diseases. AstraZeneca claims a Phase III win with its nanobody treatment for myasthenia gravis. Second-quarter earnings season is approaching, and biotechs to watch include Sarepta and others facing challenges in the biopharma industry. Genentech downsizes as priorities shift, and GSK's comeback for Blenrep is on pause as the FDA delays its decision. The FDA's lack of transparency has tarnished Sarepta's reputation after patient deaths triggered an FDA battle. Opportunities in the industry include roles like Quality Specialist at CSL and Clinical Research Physician at Eli Lilly and Company.

Julie's brand new Big Gorgeous Goals: Official Workbook can be ordered now! Grab your copy.Dr. Joan Fallon shares her journey from clinical practice to founding Curemark, a biotech company developing novel therapies for Autism based on her discovery of enzyme deficiencies in children with the condition. Her innovative approach challenges traditional pharmaceutical development by addressing the physiological root causes of Autism rather than just treating symptoms.Dr. Joan Fallon, Founder and CEO of Curemark, is a visionary scientist dedicated to improving the health and well-being of children globally. Under her leadership, Curemark has developed novel therapies for diseases with limited treatment options, including a Phase III clinical program for Autism and research on Parkinson's Disease, schizophrenia, and addiction. The company's first drug, CM-AT, targeting autism, has earned Fast Track status from the FDA. Dr. Fallon holds over 400 patents, has authored numerous scholarly articles, and is a sought-after lecturer. Recognized as one of Goldman Sachs' Top 100 Most Intriguing Entrepreneurs of 2020 and a recipient of the EY Entrepreneur Of The Year Award in 2017, she also published her first book, Goodbye, Status Quo: Reimagining the Landscape of Innovation, in 2022. A respected business leader, doctor, and academic, Joan is passionate about sharing her insights on entrepreneurship and innovation.You can connect with Dr. Joan Fallon on LinkedIn. You can also learn more about Curemark on their website.Love the show or want to request a topic? Send us a text! (All submissions are anonymous, so if you'd like a reply, please include your email address!)You can connect with Julie on LinkedIn or Instagram. Find Julie's writing at her blog or by ordering her book Big Gorgeous Goals and the brand new official companion workbook! What did you think of this conversation? We'd love if you'd rate or review our show!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The FDA has initiated a voucher program to address lower drug prices and boost domestic investment, with up to five companies being selected based on national priorities. Roche has halted shipments of Sarepta's Elevidys gene therapy after reports of patient deaths. Sarepta is under FDA scrutiny following a third patient death, while the agency welcomes a new top drug regulator and rejects multiple new drugs from entering the market. Insights from women in biopharma highlight the importance of resilience. Zhen Li, an engineer, is playing a crucial role in shaping the field of siRNA. Research suggests that GLP-1s may offer protection against neurodegenerative diseases. Dispatch Bio enters the scene with a substantial $216 million investment for universal CAR T therapy. Sarepta complies with an FDA request to suspend US shipments of Elevidys, raising concerns about transparency and impacting the company's reputation. Replimune experiences a significant drop in stock value following an FDA rejection, while AstraZeneca makes a bold $50 billion investment in US manufacturing to prepare for potential tariffs. Thank you for tuning in to Pharma and Biotech daily for the latest updates in the industry.

Ovagen Group Limited, an innovation-led Irish biotech, has announced groundbreaking results from a Yellow Fever virus yield study that could transform the economics of global vaccine manufacturing. Conducted at The Pirbright Institute (UK), a world-renowned centre tackling viral diseases of livestock, the comparative study showed that Ovagen's Germ Free embryonated chicken eggs delivered up to 7,600 doses of yellow fever virus 17D per egg compared to just 422 doses per Specified Pathogen-Free (SPF) Egg using current industry standards. With a current global shortfall of 60 million yellow fever vaccines per year, Ovagen's technology can help scale up production of yellow fever vaccine production by reducing reliance on key raw material inputs such as SPF eggs, antibiotics, and downstream processing resources. More than 140,000 eggs would be required to satisfy the current global shortfall using current industry standards compared with just 7,894 eggs using Ovagen's technology. The improved yield also dramatically reduces the volume of antibiotics typically required in conventional egg-based manufacturing, helping to mitigate risks associated with antimicrobial resistance and lowering overall production costs. Speaking about the results of the study, Dr. Catherine Caulfield, CEO of Ovagen said: "What we have developed isn't incremental, it's a complete rethink of the vaccine manufacturing process. Our germ free egg platform eliminates bacterial contamination and reduces the need for antibiotics in vaccine production, while delivering significantly higher viral yield. This is high-impact science with high-value commercial outcomes." The results of the Pirbright Institute study using Ovagen's technology demonstrated that: Ovagen Germ Free eggs resulted in 7,606 doses of Yellow Fever vaccine per egg VERSUS 6 doses & 422 doses per SPF egg, respectively, from two leading SPF egg suppliers Up to a 5-fold lower interferon beta response, boosting viral replication. The technology offers immediate scalability and significant margins for manufacturers, all while reducing waste and environmental impact. For public health systems and vaccine developers alike, it enables faster response times, lower costs, and increased resilience in the face of a public health crisis. Backed by Enterprise Ireland, Ovagen represents a standout opportunity in Europe's deep tech and biotech sectors. With growing global demand for scalable, clean, and efficient vaccine platforms, the company is now positioned for rapid international growth. Tom Cusack, Head of Industrial & Life Sciences at Enterprise Ireland, said: "Enterprise Ireland is proud to support Ovagen as they continue to scale their innovation and ambition. Their germ-free egg technology shows real potential to drive greater efficiency in vaccine manufacturing, and it's encouraging to see this level of innovation emerging from the West of Ireland. Ovagen's progress highlights the strength of Ireland's biotech sector and the impact that Irish companies can have on global health challenges." Ovagen was founded with the ambitious goal of developing the world's first commercially viable germ-free egg production system for use in biopharmaceutical manufacturing. Having secured over €21 million in funding through a mix of private investment, promoter funds, VC, EU research grants, and EIC Accelerator backing, the company has developed a state-of-the-art facility, secured global patent protection, sales traction and validated significantly higher viral yields compared to industry-standard SPF eggs. See more stories here. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to disc...

Join us for an exciting episode of The Edge of Show, live from Inscribing Vegas! In this episode, we dive deep into the intersection of art, technology, and the Bitcoin ecosystem. We kick off with Postwook, a lens-based mixed media artist, who shares insights about her unique approach to art using astronomical data and the significance of her work being displayed on the world's largest screen, the Sphere. Next, we chat with Marvin from Maestro, a blockchain infrastructure provider focused on UTXO blockchains. Then Sailor Gary, the CEO of Spirit Punks, the meme‑driven vodka company with blockchain swagger. Finally, we hear from Stephen Miller, who talks about his curated digest of the art world and his own collection, Behold. Support us through our Sponsors! ☕

On this episode of Longevity by Design, Dr. Gil Blander sits down with Dr. Karl Pfleger, aging biotechnology investor and creator of AgingBiotech.info, to dissect the rapidly evolving field of aging therapeutics. Karl breaks down the sector into two main categories: interventions that slow aging rates versus rejuvenation strategies that repair accumulated damage.Karl highlights the most promising areas in his investment portfolio, including senolytics for clearing senescent cells and epigenetic reprogramming technologies. He explains why current aging clocks aren't ready for clinical use and discusses the limitations of popular interventions like GLP-1 drugs and fasting protocols. The conversation reveals that 14 Phase 3 clinical trials are currently testing core aging therapeutics.The discussion covers recent FDA approvals for ATTR treatments and stem cell therapies, signaling the field's maturation. Karl emphasizes that meaningful life extension requires a "divide and conquer" strategy, targeting multiple aging mechanisms simultaneously rather than relying on single interventions. Despite exciting therapeutic developments, he maintains that optimizing diet, exercise, and sleep remains the most impactful strategy for extending healthspan today.Guest-at-a-Glance

Synopsis: Host Rahul Chaturvedi sits down with Jeremy Bender, CEO of Day One Biopharmaceuticals, to explore the bold mission of transforming pediatric oncology. From earning FDA approval for a groundbreaking brain cancer drug to building a culture rooted in execution and empathy, Jeremy shares lessons from big pharma and startups alike. He discusses how to lead through uncertainty, scale with discipline, and stay focused on delivering targeted therapies for underserved patients. They also dive into real-world data, AI's emerging role in clinical trial design, and why pediatric-first innovation could reshape the future of oncology. Biography: Jeremy Bender, Ph.D., M.B.A. has served as our Chief Executive Officer, President and a member of our board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, he was Vice President of Corporate Development at Allos Therapeutics, a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender also sits on the board of Mereo BioPharma as an independent board member. He started his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.

“This isn't just one gene edit—this is multiple edits, working in concert. It's a fundamentally different chassis.” In part three of The Biotech Startups Podcast, host Jon Chee and Aaron Edwards dive into the realities of biotech entrepreneurship, spotlighting the power of non-traditional career paths, self-awareness, and creative knowledge sharing. They unpack how embracing new tools, fostering open debate, and democratizing information through platforms like Notion, ELNs, and social media can drive both personal growth and startup success. The conversation highlights the importance of capital efficiency, authentic community engagement, and building a culture where diverse perspectives fuel innovation in today's fast-evolving life sciences landscape.

What happens when patients can't afford the medicine you've worked so hard to create? In this episode, host Elaine Hamm, PhD, sits down with Vinay Patel, PharmD—Chief Pharmacy Officer at Proactive MD and Founder of MakoRx—to unpack the hidden complexities behind drug pricing, access, and affordability. Together, they explore how traditional insurance models impact patient care, and what drug developers and startups need to know to ensure their therapeutics actually reach the people who need them. In this episode, you'll discover: Why pharmacy benefit managers (PBMs) influence drug access—and what that means for your commercialization strategy. How cost-plus pricing models are changing the healthcare landscape. Key considerations for biotech innovators to ensure affordability, patient access, and long-term success. Whether you're developing a new therapeutic or trying to understand the real-world implications of drug pricing, this conversation offers a powerful look behind the pharmacy counter. Links: Connect with Vinay Patel, PharmD, and check out Proactive MD and MakoRx. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about The Study, Elaine's wine bar. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Sarepta Therapeutics has halted the distribution of Elevidys in the US after the FDA request, following two deaths. The company's transparency has been called into question, affecting its stock value. Replimmune also faced setbacks after the FDA rejected its melanoma treatment, causing a significant drop in shares. On a more positive note, AstraZeneca has pledged $50 billion for US manufacturing, focusing on drugs like Baxdrostat and oral glp-1 therapies. Sanofi has made a $1.6 billion vaccine acquisition, while Biogen commits $2 billion to expand US drug production. The pharmaceutical industry is seeing various developments and challenges, with companies adapting to regulatory demands and market pressures.

This week's guest on Careers in Discovery is Michael Lutz, CEO of Iota Sciences and Osteolabs. Michael leads two innovative companies - one pioneering single-cell and stem cell handling technologies, the other developing early diagnostics for osteoporosis and bone metastasis. He shares his journey from chemist to Biotech entrepreneur, what he learns building capital-efficient businesses, and why staying close to the science keeps leadership challenging and rewarding. We talk about the realities of being a hands-on CEO in small companies, the importance of speed and execution in a crowded market, and how Michael uses communication to build trust and alignment within his teams. He also reflects on the evolving Biotech funding landscape, lessons from scaling multiple ventures, and why embracing the unknown is key to turning breakthrough ideas into successful products.

The Flyover Film Festival features a wide of array of flickering images but none is more compelling than the story of Phil Sharp. He was born in a home with a dirt floor to parents who had no high school education. Sharp goes on to earn a Nobel Prize for his work on RNA splicing.CRACKING THE CODE: Phil Sharp and the Biotech RevolutionProducer/director Bill Haney spoke with Terry Meiners about shooting this film and the challenges facing a creator in the editing process. Sharp's story is incredible, and Haney has 900 hours of film that must be whittled down to 90 minutes.This film will be screened Sunday, July 27 at the Speed Cinema.louisvillefilmsociety.org

Join us in this episode of Skin Anarchy as Dr. Ekta Yadav sits down with Ohad Bendror, founder and CEO of NanoSpun Technologies, to explore one of the most radical shifts in skincare: living, on-demand microbiome delivery. While most brands tout probiotics with shelf-stable claims, NanoSpun is building something entirely different—a biological platform that brings real, live cells directly to your skin.Ohad reveals how NanoSpun's technology works like a biotech engine—activating 100 billion+ live bacteria only when it hits your skin, preserving potency like “freshly squeezed juice.” It's not just delivery—it's a living factory in a face mask.This isn't about trends—it's about disrupting four major layers of the skincare model: real live cells, shelf-stable dormancy, on-demand activation, and functional delivery systems. The result? Postbiotics synthesized in real time, tailored to skin concerns like acne, aging, or sensitivity.NanoSpun isn't just a brand—it's a platform. From white-labeled partnerships to its in-house line Biotica 1905, it's redefining what skincare can do. Clinical results show improvements in hydration, redness, and fine lines in just weeks.If you've ever wondered what comes after serums and synthetics—this is it. Tune in to hear how NanoSpun is building the biological infrastructure of beauty and why the future of skincare is very much alive.CHAPTERS:(0:00) Introduction to NanoSpun and Ohad Bendror(1:03) The Birth of NanoSpun and Its Core Technology(2:30) Explaining Postbiotics and Their Relevance in Skincare(4:46) The Four-Layer Disruption: A New Approach to Skin Microbiome(7:51) Solving the Shelf Life Problem and Maintaining Bioavailability(9:57) The Role of Live Cell Technology in Skincare(14:03) Scaling and Customization: How NanoSpun Works for Different Skin Needs(19:19) The Future of Personalized Skincare with NanoSpun and AI(27:06) The Long-Term Roadmap and Potential of NanoSpun TechnologyTo learn more about NanoSpun, visit their website and social media.Learn more about Function Health and join using our link. The first 1000 get a $100 credit toward their membership. Visit www.functionhealth.com/SKINANARCHY or use gift code SKINANARCHY at sign-up to own your health.Please fill out this survey to give us feedback on the show!Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.

Michelle Andrews built a career inside the pharma machine long before anyone knew what “DTC” meant. She helped launch Rituxan and watched Allegra commercials teach America how to ask for pills by name. Then she landed in the cancer fun house herself, stage 4 breast cancer, and learned exactly how hollow all the “journey” slide decks feel when you're the one circling the drain.We talk about what happens when the insider becomes the customer, why pill organizers and wheat field brochures still piss her off, and how she fired doctors who couldn't handle her will to live. You'll hear about the dawn of pharma advertising, the pre-Google advocacy hustle, and what she wants every brand team to finally admit about patient experience.If you've ever wondered who decided windsurfing was the best way to sell allergy meds—or what happens when you stop caring if you make people uncomfortable—listen up.RELATED LINKSMichelle Andrews on LinkedInTrinity Life Sciences – Strategic AdvisoryJade Magazine – Ticking Time Bombs ArticleNIHCM Foundation – Breast Cancer StoryFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.George Tidmarsh, a biopharma veteran and adjunct professor at Stanford's medical school, has been appointed as the new head of the FDA's Center for Drug Evaluation and Research (CDER). His extensive industry experience will be valuable in his new government position. Data secrecy among cell and gene therapy developers is hindering progress in the field, causing fragmentation, stalling innovation, and delaying access to treatments. Meanwhile, Sarepta is facing challenges with its elevidys shipments and has lost platform designation for its technology. At the same time, Roche's phase III trial in COPD has failed, impacting the market path for astegolimab. Layoffs are happening at companies like GSK, Sail, and BioNTech. Experts are exploring new ways to overcome barriers in cell therapy production.Data secrecy among cell and gene therapy developers continues to hinder progress and access to treatments. Acadia has introduced a new team and pipeline with ambitious goals. Patients are fighting for access to Brainstorm's ALS drug after promising real-world data. Moderna's withdrawal of its flu vaccine has left combination flu/COVID-19 vaccines in limbo. In other news, Sarepta is facing challenges with its DMD gene therapy, Ultragenyx's gene therapy for Sanfilippo syndrome is rejected by the FDA, GSK's Blenrep loses an adcomm vote, and BMS' anemia drug Reblozyl fails a Phase III trial. The FDA is experiencing layoffs and employee turnover amid an overhaul. Vinay Prasad overruled reviewers on Moderna's COVID-19 shot for kids. Upcoming events include a webinar on AI for real-world research and job opportunities in the biopharma industry. Readers are encouraged to provide feedback and suggest topics for future coverage.

A surge in private market investment has Fools wondering: is it time to bet bigger on biotech? Tim Beyers and Karl Thiel discuss: - The rise in biotech funding from VCs and wealthy individuals. - The key attributes of an investable biotech. - Which is the better biotech: Viking Therapeutics or Eli Lilly? Companies discussed: VKTX, LLY, MRK Host: Tim Beyers and Karl Thiel Producer: Anand Chokkavelu Engineer: Dan Boyd, Natasha Hall Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement.Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

We love to hear from our listeners. Send us a message. On this week's episode, Dr. Hernan Bazan, M.D., co-founder and CEO at New Orleans-based South Rampart Pharma, talks about building an ultra-lean drug development company to address an unmet need observed in his own patients as a surgeon: safe treatments for acute pain. Dr. Bazan explains his strategy for building value through small raises and no full-time salaried employees, co-founding the company with his father -- a scientist and director of the Neuroscience Center of Excellence at Louisiana State University Health Sciences Center -- and why the future of pain management will likely involve multimodal approached personalized to individual patients. This episode of the Business of Biotech is brought to you by Ecolab. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Margaret Moore, faculty member at Harvard Medical School and former biotech CEO, brings decades of experience at the intersection of science, strategy, and human development to this conversation. In this episode, she unpacks The Science of Leadership, the forthcoming book she co-authored after reviewing hundreds of meta-analyses and large-scale studies, ultimately synthesizing leadership science into a framework of nine essential capacities.   Moore emphasizes the role of conscious leadership, defined as the ability to “see things clearly” by quieting internal “ego noise”, the arousal, impatience, and worry that cloud judgment. She highlights the emerging concept of the quiet ego, noting that “you're still impactful... but with a way of being quiet about it that people can absorb more easily.”   Challenging conventional strength-based approaches, Moore advocates for psychological wholeness, encouraging leaders to access underused capacities—such as empathy, creativity, and intuition—to become more balanced and mature decision-makers: “You'll be surprised that you have it there… You actually, if you pause, can access [it], like playing or being an orchestra conductor.”   She also discusses how intuition, often misunderstood as abstract, is a skill that can be developed through stillness, reflection, and experience: “Creativity is flow, and flow is when you let go of control… It's the opposite of our main mode.”   The conversation underscores the importance of strategic adaptability. Drawing on research, Moore shares that while humility doesn't improve a leader's own performance, “other people's performance is improved if you're humble. So you don't do it for yourself, you do it for them.” But she also cautions: in crises, “humility is not what people want. They want strong leaders out in front, in charge.”   Finally, Moore distinguishes between empathy and compassionate leadership, where compassion is “respect and understanding… with action,” and can be both more sustainable and effective in driving accountability.   For leaders ready to evolve beyond performance and toward genuine transformation, this conversation offers a research-grounded framework and an invitation to reflect: “In the moment, there's always the potential. If you're just awake, you will feel it. And you can act on it.”   Get Margaret's book here: https://shorturl.at/tuRKR The Science of Leadership: Nine Ways to Expand Your Impact   Here are some free gifts for you:   Overall Approach Used in Well-Managed Strategy Studies free download: www.firmsconsulting.com/OverallApproach   McKinsey & BCG winning resume free download: www.firmsconsulting.com/resumepdf   Enjoying this episode? Get access to sample advanced training episodes here: www.firmsconsulting.com/promo

Fertinagro Biotech SL ha sido reconocida con el Premio Nacional de Innovación 2025 en la modalidad modalidad Gran Empresa Innovadora, quie concede el Ministerio de Ciencia, innovación y Universidades. El jurado ha valorado su decidida apuesta por la innovación como principal vector de transformación de la industria agroalimentaria hasta convertirse en un referente internacional de la innovación agroindustrial. Además, destaca su firme compromiso con la sostenibilidad medioambiental. Ágora conversa con Sergio Atarés, director de Planificación Estratégica de Fertinagro Biotech. Y cierra el programa el presidente de la Agrupación Astronómica de Huesca, Alberto Solanes, que detalla el Ciclo Estival de Astronomía.     

 “It's an honor to be an advocate,” says Laura Bonnell, founder of The Bonnell Foundation. “We are the government—people are. If we don't fight for fair laws that help the people they're meant to serve, who will?”In this episode, Laura is joined by five passionate advocates—some seasoned, some new—who recently traveled to Washington, DC, to meet with lawmakers. Together, they share their personal experiences, insights on advocacy, and why storytelling and persistence matter in influencing policy.The conversation highlights:How to build relationships with legislative staffThe role of personal stories in driving changeThe importance of staying organized and adaptableAdvice for those who can't travel but still want to advocateThe emotional and rewarding aspects of standing up for what mattersPlus, we're joined by a lineup of experts working at the intersection of science, innovation, and policy:Dr. Andy Kocab, VP of Research at ONL Therapeutics, shares how biotech is advancing treatments for retinal diseases. Contact: akocab@onltherapeutics.comHarold Chase, Director of Government Affairs at NSF, discusses his journey from Senate staffer to global health policy leader. Contact: hchase@nsf.orgThomas T. Moga, a veteran patent attorney and Fulbright Scholar, explains how intellectual property law impacts innovation. Contact: tmoga@dykema.comDr. Brandon McNaughton, CEO of Akadeum Life Sciences, offers insight on entrepreneurship, biotech breakthroughs, and customer-focused design. Contact: bhmcnaughton@gmail.comStephen Rapundalo, President of Michbio, reflects on bridging science, business, and public service. Contact: Stephen@michbio.orgThis episode is a powerful reminder that advocacy takes many forms—and every voice matters. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Sarepta Therapeutics experienced a significant drop in shares as the FDA considers requesting a halt to shipments of the Duchenne muscular dystrophy therapy Elevidys. This decision comes after a third patient death linked to the underlying platform. The company's stock plummeted by 37% on Friday afternoon as reports of the potential shipment stop circulated in the media. This news adds to the already turbulent week for Sarepta, which has been facing challenges in its gene therapy and siRNA biotech developments. ## Novartis announced positive results from a phase 3 trial of its drug Cosentyx in treating axial spondyloarthritis. The study showed that patients treated with Cosentyx had significant improvements compared to those on a placebo. These results further solidify Novartis' position in the market for treatments of autoimmune diseases. The company plans to submit the data to regulatory authorities for potential approval of this indication.Novartis revealed encouraging outcomes from a phase 3 trial of its drug Cosentyx for treating axial spondyloarthritis. The study demonstrated that patients who received Cosentyx experienced notable enhancements compared to those who were given a placebo. These findings strengthen Novartis' standing in the autoimmune disease treatment market. The company intends to present the data to regulatory bodies for potential approval of this indication.## AstraZeneca faced setbacks as it announced delays in delivering its COVID-19 vaccine doses to the EU. The company cited production issues as the cause of the holdup, leading to frustration among European officials. This news comes at a time when vaccine distribution is crucial in combating the ongoing pandemic, highlighting the challenges faced by pharmaceutical companies in meeting global demand for vaccines.AstraZeneca encountered obstacles when it disclosed delays in distributing its COVID-19 vaccine doses to the EU. The company attributed production problems as the reason for the delay, causing frustration among European officials. This development occurs during a critical period in vaccine distribution to combat the current pandemic, underscoring the difficulties pharmaceutical companies encounter in meeting worldwide vaccine demands.## Pfizer and BioNTech announced plans to test a third dose of their COVID-19 vaccine to assess its effectiveness against new variants of the virus. The study will involve participants who have already received two doses of the vaccine and will evaluate the immune response generated by a booster shot. This initiative reflects ongoing efforts by pharmaceutical companies to adapt their vaccines to combat emerging strains of the virus.Pfizer and BioNTech unveiled intentions to examine a third dose of their COVID-19 vaccine to determine its efficacy against new virus variants. The research will include individuals who have already been administered two doses of the vaccine and will assess the immune response produced by an additional shot. This undertaking demonstrates continuous endeavors by pharmaceutical firms to modify their vaccines in response to evolving virus mutations.

Boston leads the nation in biotech development, but all of that progress comes at a cost: massive logistical challenges in the development and maintenance of IT systems. However, companies are undeterred, and are exploring new solutions every day. Read more at https://www.gamma-solutions.llc/ GAMMA SOLUTIONS, LLC City: Newton Address: 45 Nonantum St. Website: https://www.gamma-solutions.llc Email: ga.morin@gamma-solutions.llc

Research funded by the federal government has been crucial in many of the defining technologies of our time: the internet, A.I., crispr, Ozempic, and the mRNA vaccines first used widely in the COVID pandemic. Between 2010 and 2019, more than 350 drugs were approved in the United States, and virtually all of them could trace their roots to the National Institutes of Health (NIH). Now this administration is endangering our health by cutting funds to academic medical centers. Moreover, there are threats to Medicaid, as well as ongoing cuts to the Centers for Disease Control (CDC). Many universities have paused hiring due to the uncertainty at the NIH and are curtailing graduate programs. Biotech investors are warning of a contraction in medical innovation. NIH grants have been terminated on ideological grounds, which have resulted in clinical trials shutting down. Global health programs worldwide have been cut. A discussion on these destructive policies on medicine in our country is needed. About the Speaker Monica Gandhi M.D., M.P.H., is a professor of medicine and associate chief in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco (UCSF). She is also the director of the UCSF Center for AIDS Research (CFAR) and the medical director of the HIV Clinic ("Ward 86") at San Francisco General Hospital. She serves as the associate program director of the ID fellowship at UCSF. Her research focuses on HIV treatment and prevention optimization, HIV and women, adherence measurement in HIV and TB, adherence interventions, and on optimizing the use of long-acting antiretroviral therapy (ART). She is a long-standing NIH-funded researcher. Commonwealth Club World Affairs of California is a nonprofit public forum; we welcome donations made during registration to support the production of our programming. A Health & Medicine Member-led Forum program. Forums and Chapters at the Club are organized and run by volunteer programmers who are members of The Commonwealth Club, and they cover a diverse range of topics. Learn more about our Forums. Commonwealth Club World Affairs is a public forum. Any views expressed in our programs are those of the speakers and not of Commonwealth Club World Affairs. OrganizerMichael Baker  Learn more about your ad choices. Visit megaphone.fm/adchoices

Synopsis: What do courtroom litigation, computational biology, and fibrosis drug development have in common? In this episode of Biotech 2050, host Alok Tayi speaks with Ahmed Mousa, CEO of Vicore Pharma, to explore his unconventional journey from biotech law to the C-suite. Ahmed shares how Vicore is advancing a first-in-class therapy targeting the angiotensin II type 2 receptor to treat idiopathic pulmonary fibrosis (IPF)—a devastating disease with limited options and poor survival. The conversation dives into how AI is reshaping drug discovery, the promise of precision in early-stage candidate design, and the regulatory and data challenges biotech must overcome. Ahmed also reflects on leading a Swedish-listed biotech as an American CEO, and how a patient-first mission continues to fuel bold innovation across continents. Biography: Ahmed Mousa is the Chief Executive Officer of Vicore Pharma (VICO.ST), where he leads the company's mission to advance angiotensin II type 2 receptor agonists for the treatment of idiopathic pulmonary fibrosis and other serious diseases. Under his leadership, Vicore continues to expand its clinical pipeline and global presence in respiratory and fibrotic diseases. Previously, Ahmed served as Senior Vice President, Chief Business Officer, and General Counsel at Pieris Pharmaceuticals (PIRS). In this role, he was the site head for the company's Boston office and oversaw business development, portfolio strategy, centralized project leadership, and quality assurance. He also led Pieris' legal and intellectual property functions, including licensing, corporate governance, and management of the company's global patent portfolio. Before joining Pieris, Ahmed was an attorney at Covington & Burling LLP, where he advised pharmaceutical and biotechnology companies on a range of regulatory and intellectual property matters. He also served as a law clerk for the U.S. Court of Appeals for the Third Circuit and began his legal career as an IP associate at Kirkland & Ellis LLP. Ahmed holds dual undergraduate degrees in Molecular Biology and Government from Cornell University, a Master's in Biotechnology from Johns Hopkins University, and a J.D. with honors from Georgetown Law, where he was Editor-in-Chief of the Georgetown Journal of International Law.

Bitcoin; Bonds; Tariffs; Ukraine; Asylum; Biotech & China | Yaron Brook Show

Dr. Anne Marie Morse walks into the studio like a one-woman Jersey Broadway show and leaves behind the best damn TED Talk you've never heard. She's a neurologist, sleep medicine doc, narcolepsy expert, founder of D.A.M.M. Good Sleep, and full-time myth buster in a white coat. We talk about why sleep isn't a luxury, why your mattress does matter, and how melatonin is the new Flintstones vitamin with a marketing budget. We unpack the BS around sleep hygiene, blow up the medical gaslighting around “disorders,” and dig into how a former aspiring butterfly became one of the loudest voices for patient-centered science. Also: naps, kids, burnout, CPAPs, co-sleeping, airport pods, the DeLorean, and Carl Sagan. If you think you're getting by on five hours of sleep and vibes, you're not. This episode will make you want to take a nap—and then call your doctor.RELATED LINKSdammgoodsleep.com: https://www.dammgoodsleep.comLinkedIn: https://www.linkedin.com/in/anne-marie-morse-753b2821/Instagram: https://www.instagram.com/dammgoodsleepDocWire News Author Page: https://www.docwirenews.com/author/anne-marie-morseSleep Review Interview: https://sleepreviewmag.com/practice-management/marketing/word-of-mouth/sleep-advocacy-anne-marie-morse/Geisinger Bio: https://providers.geisinger.org/provider/anne-marie-morse/756868SWHR Profile: https://swhr.org/team/anne-marie-morse-do-faasm/FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We love to hear from our listeners. Send us a message. On this week's episode, Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, how he spun his academic discoveries out into a biotech company developing new obesity drugs, the need for obesity treatments with fewer side effects than currently available GLP-1 therapies, and the value of pairing scientific leadership with a strong business partner as CEO. This episode of the Business of Biotech is brought to you by Ecolab. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/